Kinza Irshad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kinza Irshad has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Anaya Noor
Department of Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Arej Iltaf
Department of Medicine, Khyber Girls Medical College, Peshawar, Pakistan
1 shared publication - Ashfaq Ahmad
Department of Medicine, Gomal Medical College, Dera Ismail Khan, Pakistan
1 shared publication - Bhawan Kumar
Department of Internal Medicine, Dow University of Health Sciences, Karachi 75600, Pakistan
1 shared publication - Christopher Hanani
Department of Neurology, Henry Ford Health, Warren, Michigan, USA
1 shared publication - Eiman Anwar
Department of Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6258
Mortality Trends Involving Cardiac Arrest and Fluid, Electrolyte, and Acid–Base Disorders in U.S. Adults, 2004–2024
Background/Objectives: Cardiac arrest and fluid, electrolyte, and acid–base disorders frequently coexist in critically ill patients and are associated with poor clinical outcomes. However, long-term population-level trends in mortality involving both conditions remain poorly characterized. This study evaluated temporal trends and demographic disparities in mortality involving cardiac arrest and fluid, electrolyte, and acid–base disorders among U.S. adults from 2004 to 2024. Methods: We conducted a retrospective population-based study using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) Multiple Cause of Death database. Adults aged ≥25 years with cardiac arrest (ICD-10: I46) and fluid, electrolyte, and acid–base disorders (ICD-10: E87) listed anywhere on the same death certificate between 2004 and 2024 were included. Age-adjusted mortality rates (AAMRs) were calculated using the 2000 U.S. standard population. Joinpoint regression was used to estimate annual percent change (APC) and average annual percent change (AAPC), with analyses stratified by demographic and geographic characteristics. Results: A total of 152,937 deaths involved both cardiac arrest and fluid, electrolyte, and acid–base disorders during the study period. The AAMR nearly doubled, increasing from 2.06 (95% CI, 2.00–2.13) in 2004 to 4.08 (95% CI, 4.00–4.16) in 2024, corresponding to an overall AAPC of 3.42% (95% CI, 2.58–4.26; p < 0.001). Mortality remained consistently higher among males, adults aged ≥65 years, and non-Hispanic Black individuals, with significant increases observed across all demographic groups. The West demonstrated the highest regional mortality burden (AAPC, 3.75%; p < 0.001). Urbanization analyses (2004–2020) showed higher mortality in non-metropolitan than metropolitan areas (AAPCs, 5.36% vs. 4.13%; both p < 0.001). Mortality increased through 2021 before declining modestly during 2021–2024. Conclusions: Mortality involving both cardiac arrest and fluid, electrolyte, and acid–base disorders increased substantially in the United States over the past two decades, with persistent disparities in age, sex, race/ethnicity, and geography. These findings identify populations at increased risk and support targeted public health strategies, equitable healthcare access, and improved recognition and management of metabolic disturbances in patients at risk for cardiac arrest.
- 13 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6258
Open AccessMortality Trends Involving Cardiac Arrest and Fluid, Electrolyte, and Acid–Base Disorders in U.S. Adults, 2004–2024
Background/Objectives: Cardiac arrest and fluid, electrolyte, and acid–base disorders frequently coexist in critically ill patients and are associated with poor clinical outcomes. However, long-term population-level trends in mortality involving both conditions remain poorly characterized. This study evaluated temporal trends and demographic disparities in mortality involving cardiac arrest and fluid, electrolyte, and acid–base disorders among U.S. adults from 2004 to 2024. Methods: We conducted a retrospective population-based study using the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) Multiple Cause of Death database. Adults aged ≥25 years with cardiac arrest (ICD-10: I46) and fluid, electrolyte, and acid–base disorders (ICD-10: E87) listed anywhere on the same death certificate between 2004 and 2024 were included. Age-adjusted mortality rates (AAMRs) were calculated using the 2000 U.S. standard population. Joinpoint regression was used to estimate annual percent change (APC) and average annual percent change (AAPC), with analyses stratified by demographic and geographic characteristics. Results: A total of 152,937 deaths involved both cardiac arrest and fluid, electrolyte, and acid–base disorders during the study period. The AAMR nearly doubled, increasing from 2.06 (95% CI, 2.00–2.13) in 2004 to 4.08 (95% CI, 4.00–4.16) in 2024, corresponding to an overall AAPC of 3.42% (95% CI, 2.58–4.26; p < 0.001). Mortality remained consistently higher among males, adults aged ≥65 years, and non-Hispanic Black individuals, with significant increases observed across all demographic groups. The West demonstrated the highest regional mortality burden (AAPC, 3.75%; p < 0.001). Urbanization analyses (2004–2020) showed higher mortality in non-metropolitan than metropolitan areas (AAPCs, 5.36% vs. 4.13%; both p < 0.001). Mortality increased through 2021 before declining modestly during 2021–2024. Conclusions: Mortality involving both cardiac arrest and fluid, electrolyte, and acid–base disorders increased substantially in the United States over the past two decades, with persistent disparities in age, sex, race/ethnicity, and geography. These findings identify populations at increased risk and support targeted public health strategies, equitable healthcare access, and improved recognition and management of metabolic disturbances in patients at risk for cardiac arrest.
- Open Access
- 21 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1680-1686
A narrative review on the neurobiology of lucid dreaming: mechanisms and therapeutic potential
Background: Lucid dreaming (LD), which involves being aware of and controlling one’s dreams, is of particular interest in the study of consciousness and has potential therapeutic applications. In this narrative review, we highlight the neurobiological aspects of LD, specifically its mechanisms associated with the activation of prefrontal and parietal areas, increased gamma oscillations, and the influence of cholinergic and dopaminergic signaling, primarily during rapid eye movement (REM) sleep. Objective: To evaluate human data on brain mechanisms and clinical effects, synthesizing the neurobiological foundations and therapeutic possibilities of LD, including remarkably controlled lucid dreams. Methods: A narrative review of peer-reviewed research involving clinical groups [e.g., post-traumatic stress disorder (PTSD), chronic nightmares, Parkinson’s] and healthy individuals (18–45) was synthesized. Objective lucidity verification [vented eye movements, electroencephalography (EEG)/functional magnetic resonance imaging] was a requirement for inclusion criteria. Neurobiological indicators (gamma, alpha, beta waves, and prefrontal cortex/parietal activation), therapeutic benefits (e.g., frequency of nightmares, PTSD and anxiety scores, motor and cognitive gains), and safety and ethical considerations (dissociation and sleep disruption) were among the outcomes evaluated. Results: LD demonstrates efficacy in modulating nightmares, improving cognitive functions, and potentially alleviating some symptoms in PTSD and neurodegenerative disorders, albeit with methodological constraints. Developments in portable EEG and virtual reality headsets will refine LD research, while interdisciplinary approaches are necessary to address potential risks of dissociation and privacy concerns. Conclusion: Although evidence remains preliminary, LD shows promise as a therapeutic remedy for PTSD and anxiety symptoms, including a reduction in nightmares. It combines neuroscience and self-agency, highlighting the need for more funding and public awareness campaigns to harness its scientific and clinical prospects. Larger randomized trials with a variety of groups and standardized induction techniques are necessary to verify long-term efficacy and safety.
- 21 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1680-1686
Open AccessA narrative review on the neurobiology of lucid dreaming: mechanisms and therapeutic potential
Background: Lucid dreaming (LD), which involves being aware of and controlling one’s dreams, is of particular interest in the study of consciousness and has potential therapeutic applications. In this narrative review, we highlight the neurobiological aspects of LD, specifically its mechanisms associated with the activation of prefrontal and parietal areas, increased gamma oscillations, and the influence of cholinergic and dopaminergic signaling, primarily during rapid eye movement (REM) sleep. Objective: To evaluate human data on brain mechanisms and clinical effects, synthesizing the neurobiological foundations and therapeutic possibilities of LD, including remarkably controlled lucid dreams. Methods: A narrative review of peer-reviewed research involving clinical groups [e.g., post-traumatic stress disorder (PTSD), chronic nightmares, Parkinson’s] and healthy individuals (18–45) was synthesized. Objective lucidity verification [vented eye movements, electroencephalography (EEG)/functional magnetic resonance imaging] was a requirement for inclusion criteria. Neurobiological indicators (gamma, alpha, beta waves, and prefrontal cortex/parietal activation), therapeutic benefits (e.g., frequency of nightmares, PTSD and anxiety scores, motor and cognitive gains), and safety and ethical considerations (dissociation and sleep disruption) were among the outcomes evaluated. Results: LD demonstrates efficacy in modulating nightmares, improving cognitive functions, and potentially alleviating some symptoms in PTSD and neurodegenerative disorders, albeit with methodological constraints. Developments in portable EEG and virtual reality headsets will refine LD research, while interdisciplinary approaches are necessary to address potential risks of dissociation and privacy concerns. Conclusion: Although evidence remains preliminary, LD shows promise as a therapeutic remedy for PTSD and anxiety symptoms, including a reduction in nightmares. It combines neuroscience and self-agency, highlighting the need for more funding and public awareness campaigns to harness its scientific and clinical prospects. Larger randomized trials with a variety of groups and standardized induction techniques are necessary to verify long-term efficacy and safety.